Adam’s Take

Adam's Take Adam Feuerstein

STAT Plus: Argenx readies another blockbuster opportunity with its antibody drug

Adam's Take Adam Feuerstein

STAT Plus: An inside look at PIPEs, the financing trend that has biotech abuzz

Adam's Take Adam Feuerstein

STAT Plus: Ocular Therapeutix moves in the right direction, and Alnylam tries to calm some nerves

Adam's Take Adam Feuerstein

STAT Plus: Gaming Amylyx stock reactions to the next ALS drug test, and a chat with CRISPR’s CEO about a new investor

Adam's Take Adam Feuerstein

STAT Plus: A looming cancer vaccine test for Gritstone Bio, and pushback about Novartis-MorphoSys

Adam's Take Adam Feuerstein

STAT Plus: Why Novartis is going to walk away from its acquisition of MorphoSys

Adam's Take Adam Feuerstein

STAT Plus: Can gene therapies make for a profitable business? Keep your eye on Bluebird Bio

Adam's Take Adam Feuerstein

STAT Plus: What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s surprising rise

Adam's Take Adam Feuerstein

STAT Plus: FDA’s Peter Marks seems inclined to grant full approval to Sarepta’s Duchenne gene therapy

Adam's Take Adam Feuerstein

STAT Plus: A single drug and multiple study failures leave Anavex with nothing but cash

Adam's Take Adam Feuerstein

STAT Plus: Here are the worst biopharma CEOs of 2023

Adam's Take Adam Feuerstein

STAT Plus: Here are the best biopharma CEOs of 2023

Adam's Take Adam Feuerstein

STAT Plus: After sickle-cell screwups, Bluebird Bio’s only option might be a company sale

Adam's Take Adam Feuerstein

STAT Plus: MoonLake’s credibility takes another hit with mid-stage study spin job

Adam's Take Adam Feuerstein

STAT Plus: Astellas shows enough data for eye treatment to support expanded use, but still lags competitor

Adam's Take Adam Feuerstein

STAT Plus: Cassava pulled back the curtain on its Alzheimer’s study — and revealed insurmountable problems

Adam's Take Adam Feuerstein

STAT Plus: Roivant’s CEO is a star, but even a blockbuster deal can’t escape biotech’s black hole

Adam's Take Adam Feuerstein

STAT Plus: Bristol ‘take-under’ of Mirati is not so great for biotech, but company’s new cancer target has potential

Adam's Take Adam Feuerstein

STAT Plus: The Apellis eye drug rebound accelerates. This time, it’s a competitor falling behind

Adam's Take Adam Feuerstein

STAT Plus: What’s behind the recent surge in Apellis’ stock price? Growing confidence in the safety of its eye treatment

Adam's Take Adam Feuerstein

STAT Plus: Anavex, maker of rare disease drug, keeps shifting the goalposts in its clinical trials

Adam's Take Adam Feuerstein

STAT Plus: A conflict of interest behind the warning on Apellis’ eye drug? The optics are not good

Adam's Take Adam Feuerstein

STAT Plus: Moonlake’s less-than-transparent data disclosures produced a cash windfall. Risks remain

Adam's Take Adam Feuerstein

STAT Plus: Instead of credible data, PDS Biotech delivers ‘results might get better, later’ promises

Adam's Take Adam Feuerstein

STAT Plus: Annexon’s trial of an eye disease drug missed by a mile. The company saw a bull’s eye

Adam's Take Adam Feuerstein

STAT Plus: Amylyx’s ALS drug launch starts strong. That could be trouble for the FDA

Adam's Take Adam Feuerstein

STAT Plus: For Cytokinetics, an FDA rejection of its heart drug would help, not hinder

Adam's Take Adam Feuerstein

STAT Plus: Once high-flying Rubius to shut down. Its flameout is a lesson for biotech

Adam's Take Adam Feuerstein

STAT Plus: Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn